The new
biologic drug has shown remarkable efficacy in treating rheumatoid arthritis.
这种新的生物制剂药物在治疗类风湿性关节炎方面显示出了显著的疗效。
Biologic farming practices focus on enhancing soil health and biodiversity without synthetic chemicals.
生物农业实践侧重于在不使用合成化学物质的情况下增强土壤健康和生物多样性。
The company specializes in developing
biologics for cancer immunotherapy, harnessing the body's immune system to fight tumors.
该公司专门开发用于癌症免疫疗法的生物制剂，利用身体的免疫系统来对抗肿瘤。
Biologic medications derived from living organisms are revolutionizing the treatment of autoimmune diseases.
来自生物体的生物药物正在彻底改变自身免疫性疾病治疗方法。
The
biologic preserve is home to numerous endangered species, providing them with a protected natural habitat.
这个生物保护区是许多濒危物种的家园，为它们提供了受保护的自然栖息地。
The approval process for
biologic drugs is rigorous due to their complex nature and potential side effects.
由于生物药物的复杂性和潜在副作用，其审批过程非常严格。
Biologic seed treatments can improve crop yields by promoting beneficial microbial activity in the soil.
生物种子处理可以通过促进土壤中有益微生物的活动来提高作物产量。
The study of
biologic clocks has shed light on how disruptions in our circadian rhythms can impact health.
对生物钟的研究揭示了我们的昼夜节律如何被打乱以及这对健康的影响。
The development of
biologic仿制药 (biosimilars) aims to increase accessibility to these life-saving treatments at a lower cost.
生物类似药的开发旨在以较低的成本增加获得这些挽救生命的治疗手段的机会。
The use of
biologic pest control methods in agriculture reduces reliance on harmful pesticides, promoting environmental sustainability.
农业中使用生物防治方法减少了对有害杀虫剂的依赖，促进了环境可持续性。
The company has also established strategic partnerships with various China-based biotech and tech companies such as Innovent Biologic, Insilico Medicine, Adagene and Baidu, to accelerate its pace in fields including oncology, AI drug discovery and antibody development technology.
该公司还与Innovent Biologic、Insilico Medicine、Adagene和百度等多家中国生物技术公司建立了战略合作伙伴关系，以加快其在肿瘤学、人工智能药物发现和抗体开发技术等领域的步伐。
Clover Biopharmaceuticals Ltd, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced on Wednesday the construction of a new research and development center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
三叶草生物制药有限公司，一家开发新型疫苗和候选生物治疗药物的全球临床生物技术公司，周三宣布在上海张江生物技术和制药工业基地建设一个新的研发中心。
Among them, the first approval in China for the melanoma indication took only five months from filing to approval, registering the fastest approval for an imported biologic in the country.
其中，黑色素瘤适应症的上市申请更创下了从申报到获批仅5个月的记录，成为目前在中国获批最快的进口生物制剂。
Clover Biopharmaceuticals, a clinical-stage Chinese biotech developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, announced on Wednesday an advance purchase agreement with Gavi, or the Vaccine Alliance.
中国临床阶段生物技术公司Clover Biopharmaceuticals周三宣布与全球疫苗免疫联盟(Gavi, 简称：疫苗联盟)达成预购协议。Clover Biopharmaceuticals是一家致力于开发创新疫苗和生物治疗候选药物、旨在应对世界上最致命疾病和公共卫生威胁的中国临床阶段生物技术公司。
The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.
这些资金将用于支持Clover持续开发和扩展其利用创新且专有的Trimer-Tag技术平台开发的蛋白质基疫苗和生物癌症疗法管线。
Michael Yi, co-CIO and partner of Hillhouse Capital, said Clover has had a tremendous year of growth with the rapid advancement of the COVID-19 S-Trimer vaccine candidate through clinical development, and its robust and differentiated pipeline of vaccines and biologic therapeutics hold great promise to make a difference in other areas.
高瓴资本的联席首席投资官及合伙人Michael Yi表示，Clover在COVID-19 S-Trimer疫苗候选产品快速推进临床开发的推动下，度过了一个增长迅猛的年份。该公司丰富且具有差异化的疫苗和生物治疗药物管线显示出巨大的潜力，有望在其他领域产生影响。
The online recruitment of volunteers will commence with the recruitment of 960 healthy participants, aged between 18 and 85, to assess the safety and immunogenicity of the vaccine candidate and to support future biologic license applications in China.
在线志愿者招募将首先招募960名18至85岁的健康参与者，以评估疫苗候选人的安全性和免疫原性，并支持未来在中国的生物制品许可申请。
The enormous growth this year came mainly from the launch of a biologic injection to treat cardiovascular disease, and the product was moving much faster than anticipated, Penny Wan, vice-president and general manager of Amgen Japan, Australia and Asia-Pacific, said during an interview with China Daily.
A remedy that receives fast track designation may be eligible for frequent communication with the FDA, priority review, potential accelerated approval according to data and rolling submission, which allows a company to submit completed sections of its Biologic License Application or New Drug Application for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be submitted.
It is meaningless to cultivate talents only for the individual, instead of for organizations, said Xia Nan, director of human resources of Taibang Biologic Group.
“泰邦生物集团人力资源总监夏楠表示，仅为个体而培养人才，而非为组织，这是没有意义的。”
未经许可，严禁转发。QQ交流群：688169419